Detalhe da pesquisa
1.
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
N Engl J Med
; 386(23): 2188-2200, 2022 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35443106
2.
Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.
J Infect Dis
; 227(10): 1153-1163, 2023 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36683419
3.
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
Clin Infect Dis
; 76(7): 1247-1256, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36411267
4.
RNASeq_similarity_matrix: visually identify sample mix-ups in RNASeq data using a 'genomic' sequence similarity matrix.
Bioinformatics
; 2019 Nov 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31769800
5.
Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigen-presenting cells in skin.
FASEB J
; 31(2): 526-543, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27825106
6.
Predicting the risk of rheumatoid arthritis and its age of onset through modelling genetic risk variants with smoking.
PLoS Genet
; 9(9): e1003808, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24068971
7.
Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.
Oncologist
; 19(4): 318-27, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24682463
8.
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.
Infect Dis Ther
; 13(6): 1253-1268, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38703336
9.
Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial.
Infect Dis Ther
; 13(3): 521-533, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38403865
10.
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.
Infect Dis Ther
; 12(9): 2269-2287, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37751015
11.
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.
Lancet Microbe
; 4(11): e863-e874, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37783221
12.
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Lancet
; 377(9769): 914-23, 2011 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-21376385
13.
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Respir Med
; 10(10): 985-996, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35688164
14.
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
JAMA Dermatol
; 157(11): 1279-1288, 2021 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34406364
15.
Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02.
Nat Commun
; 10(1): 1150, 2019 03 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30850646
16.
Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.
Eur Neuropsychopharmacol
; 27(8): 795-808, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28576350
17.
Validation of the standardised assessment of personality--abbreviated scale in a general population sample.
Personal Ment Health
; 9(4): 250-7, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26314385
18.
ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial.
Arthritis Res Ther
; 16(1): R13, 2014 Jan 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-24433430